Die 4 wichtigsten Arbeiten zu.....
Etravirin (Intelence®)
#606 Lack of Interaction between Etravirine and Raltegravir plus Darunavir/Ritonavir When Combined in Treatment experienced Patients: A Substudy of the ANRS 139 TRIO Trial
A Barrail-Tran1, Y Yazdanpanah2, C Fagard3, C Colin3, C Piketty4,C Katlama5, D Descamps6, J-M Molina7, G Chêne3, Anne-Marie Taburet*1,and ANRS 139 Study Group
1Hosp Bicetre, AP-HP, Paris, France; 2Hosp Tourcoing, France; 3INSERM U897, Bordeaux, France; 4Hosp Georges Pompidou, AP-HP, Paris, France; 5Hosp Pitie-Salpetriere, AP-HP, Paris, France; 6Hosp Bichat Claude Bernard, AP-HP, Paris, France; and 7Hosp Saint Louis, AP-HP, Paris, France
#593 Bulk and Clonal Resistance Analyses in Highly Experienced Patients Failing Raltegravir, Etravirine, and Darunavir/ritonavir Containing Regimen (ANRS 139 TRIO Trial)
B Roquebert1, C Colin2, A-M Taburet3, C Fagard2, C Katlama4, J-M Molina5,C Jacomet6, G Chêne2, Y Yazdanpanah7, Diane Descamps*1, and the ANRS139 TRIO Trial Study Group
1Univ Paris Diderot, Hosp Bichat Claude Bernard, Paris, France; 2INSERM U897, Bordeaux, France; 3Hosp Bicetre, Le Kremlin-Bicetre, France; 4Hosp Pitie-Salpetriere, Paris, France; 5Univ Paris Diderot, Hosp Saint Louis, Paris, France; 6Hosp Clermont-Ferrand, France; and 7Hosp Tourcoing, France
#593 Improved Genotypic Algorithm for Predicting Etravirine Susceptibility: Comprehensive List of Mutations Identified through Correlation with Matched Phenotype
Mojgan Haddad*, E Stawiski, J Benhamida, and E Coakley
Monogram Biosci, Inc, South San Francisco, CA, US
#553 Resistance Associated Mutations to Etravirine in Antiretroviral-naïve Patients Infected with Non-B HIV-1 Subtypes
A Maiga1, D Descamps2, L Morand-Joubert1, M Cisse3, A Capt4,C Katlama1, D Costagliola1, B Masquelier5, V Calvez1, and Anne-Geneviève Marcelin*1
1INSERM U943, Hosp Pitie-Salpetriere, Paris, France; 2Hosp Bichat Claude Bernard, Paris, France; 3CESAC, Bamako, Mali; 4Virco, Mechelen, Belgium; and 5Ctr Hosp Univ Bordeaux, France
Kollegen Fragen
